Andrew has more than three decades of experience in senior international commercial leadership positions within the Pharmaceuticals and Medical Devices sectors. With a specialization in early access pre-approval unlicensed medicines, he holds key responsibilities in leadership, commercial operations and financial performance. Andrew has had a significant contribution to facilitating medicine access throughout his tenure at Idis/Clinigen, Caligor, Inceptua, and is now Director of Early Access Programmes at Sciensus, Rare Diseases.
Andrew Cummins
Director of Expanded Access Programs
Latest Articles by Expert
View the latest articles written our expert
Blogs/Articles, Rare diseases
Mitigating Risks in Early Access Programs: A Guide for Biotech Companies
Thought Leadership, Rare diseases
Leveraging Early Access Programs and Real-World Data for commercial success
Blogs/Articles, Rare diseases
Out-licensing vs partnering: Strategies for accessing Europe